Sanofi : A role to play in a market still to be evangelised
>Proven efficacy, reassuring safety of use - Last Friday, Sanofi published the complete results of its HERCULES trial evaluating tolebrutinib in non-relapsing secondary progressive multiple sclerosis (nrSPMS) and GEMINI in the remittent form of the disease (RMS). We already knew the positive profile of the clinical results for HERCULES, but not necessarily the specifics. In concrete terms, tolebrutinib delays by 31% the time to disease progression to 6 months relative...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.